In PN-associated metabolic bone disease, which statement is true regarding screening recommendations for patients on PN longer than 1 year?

In PN-associated metabolic bone disease, which statement is true regarding screening recommendations for patients on PN longer than 1 year?

• A. All patients on PN longer than 1 year should be recommended for DEXA.
• B. DEXA is not recommended in PN patients.
• C. Only patients with bone pain require DEXA.
• D. Annual calcium checks replace DEXA.

Answer: (A)

Bone health can deteriorate quietly in people on parenteral nutrition for extended periods because of limited mobility, uneven mineral supply (calcium, phosphorus), and suboptimal vitamin D status. Since bone loss may occur before symptoms or pain appears, objective testing is needed rather than waiting for signs. DEXA, a precise measure of bone mineral density, provides a baseline and tracks changes over time, helping identify osteopenia or osteoporosis early and guide treatment decisions. Therefore, recommending DEXA for all patients on PN for more than a year is the best approach. It ensures you quantify bone density, monitor progression, and tailor interventions (nutrition optimization, vitamin D/calcium supplementation, or other therapies) rather than relying on symptoms or simple calcium checks, which do not reflect bone density. The other options underestimate the value of objective bone density assessment or rely on non-definitive clues like bone pain or biochemical calcium alone to assess fracture risk.

Bone health can deteriorate quietly in people on parenteral nutrition for extended periods because of limited mobility, uneven mineral supply (calcium, phosphorus), and suboptimal vitamin D status. Since bone loss may occur before symptoms or pain appears, objective testing is needed rather than waiting for signs. DEXA, a precise measure of bone mineral density, provides a baseline and tracks changes over time, helping identify osteopenia or osteoporosis early and guide treatment decisions.

Therefore, recommending DEXA for all patients on PN for more than a year is the best approach. It ensures you quantify bone density, monitor progression, and tailor interventions (nutrition optimization, vitamin D/calcium supplementation, or other therapies) rather than relying on symptoms or simple calcium checks, which do not reflect bone density. The other options underestimate the value of objective bone density assessment or rely on non-definitive clues like bone pain or biochemical calcium alone to assess fracture risk.